ABSTRACT
The spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic that has claimed the lives of millions of people. Genomic surveillance of the virus has proven to be a critical tool for tracking the emergence and spread of variants with increased transmission or immune evasion potential. Despite the global distribution of infection, differences in viral genomic surveillance capabilities between countries and regions have resulted in gaps in our understanding of the viral population dynamics underlying the pandemic. Nigeria, despite having the largest population of any country in Africa, has had relatively little SARS-CoV-2 sequence data made publicly available. In this study, we report the whole-genome sequences of 74 SARS-CoV-2 isolates collected from individuals in Oyo State, Nigeria over the first two weeks of January 2021. Forty-six of the isolates belong to the B.1.1.7 “UK variant” lineage. Comparison to available regional and global sequences suggest that the B.1.1.7 isolates in Nigeria are primarily monophyletic, possibly representing a singular successful introduction into the country. The majority of the remaining isolates (17 of 74) belong to the B.1.525 lineage, which contains multiple spike protein mutations, including the E484K mutation associated with potential immune escape. Indeed, Nigeria has the highest reported frequency of this lineage despite its relative rarity worldwide. Phylogenetic analysis of the B.1.525 isolates in this study relative to other local and global isolates suggested a recent origin and rapid expansion of this lineage in Nigeria, with the country serving as a potential source for this lineage in other outbreaks. These results demonstrate the importance of genomic surveillance for identifying SARS-CoV-2 variants of concern in Nigeria and in other undersampled regions across the globe.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported in part through the computational resources and staff contributions provided for the Quest high performance computing facility at Northwestern University, which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. Funding for this work was provided by: a Northwestern Institute for Global Health Catalyzer Research Fund award (R.L.R. and O.M.A.); a Dixon Translational Research Grant made possible by the generous support of the Dixon Family Foundation (E.A.O. and J.F.H.); a COVID-19 Supplemental Research award from the Northwestern Center for Advanced Technologies (NUCATS - J.F.H.); a CTSA supplement to NCATS UL1 TR002389 (J.F.H., E.A.O., R.L.R.); a supplement to the Northwestern University Cancer Center P30 CA060553 (J.F.H.); the Gilead Sciences Research Scholars Program in HIV (J.F.H.); the NIH-supported Third Coast CFAR P30 AI117943 (R.L.R., J.F.H.); NIH grant K22 AI136691 (J.F.H.); NIH grant U19 AI135964 (E.A.O.); NIH grant D43 TW009608 (B.O.T., O.M.A.); NIH Fogarty International Center award D43TW009608 (B.O.T.); and through a generous contribution from the Walder Foundation (J.F.H., E.A.O., R.L.R.). The authors also acknowledge the Nigeria Center for Disease Control (NCDC) for providing leadership and infrastructure that facilitated collection of samples included in this study. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the National Health Research Ethics Committee of Nigeria (NHREC)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Fixed typo in the title
Data Availability
The final 74 complete SARS-CoV-2 genomes were deposited in the publicly available GISAID database (Supplemental Table 1)